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Background: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that lacks 
any disease-modifying drug for the prevention and treatment. Edaravone (EDR), an approved free 
radical scavenger, has proven to have potential against AD by targeting multiple key pathologies 
including amyloid-beta (Aβ), tau phosphorylation, oxidative stress, and neuroinflammation. 
To enable its oral use, novel edaravone formulation (NEF) was previously developed. The 
aim of the present investigation was to evaluate safety and efficacy of NEF by using in vitro/
in vivo disease model.
Materials and methods: In vitro therapeutic potential of NEF over EDR was studied against 




 and Aβ42 oligomer, and cellular uptake on 
SH-SY5Y695 amyloid-β precursor protein (APP) human neuroblastoma cell line. For in vivo safety 
and efficacy assessment, totally seven groups of APP/PS1 (five treatment groups, one each as a 
basal and sham control) and one group of C57BL/6 mice as a positive control for behavior tests 
were used. Three groups were orally treated for 3 months with NEF at an equivalent dose of EDR 
46, 138, and 414 µmol/kg, whereas one group was supplied with each Donepezil (5.27 µM/kg) and 
Soluplus (amount present in NEF of 414 µmol/kg dose of EDR). Behavior tests were conducted to 
assess motor function (open-field), anxiety-related behavior (open-field), and cognitive function 
(novel objective recognition test, Y-maze, and Morris water maze). For the safety assessment, 
general behavior, adverse effects, and mortality were recorded during the treatment period. More-
over, biochemical, hematological, and morphological parameters were determined.
Results: Compared to EDR, NEF showed superior cellular uptake and neuroprotective effect 
in SH-SY5Y695 APP cell line. Furthermore, it showed nontoxicity of NEF up to 414 µM/kg 
dose of EDR and its potential to reverse AD-like behavior deficits of APP/PS1 mice in a dose-
dependent manner. 
Conclusion: Our results indicate that oral delivery of NEF holds a promise as a safe and effec-
tive therapeutic agent for AD. 
Keywords: edaravone, Soluplus, dose–response relationship, APPSwe/PS1deE9 mice, learning 
and memory, safety assessment 
Introduction
Due to modern advancement in medical technology to combat dreadful diseases and 
providing a high quality of life in the 21st century, the aging population is increasing.1 
Alzheimer’s disease (AD), the most common cause of dementia, is a chronic neuro-
degenerative disease linked to the progressive cognitive deficits specifically in elder 
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community with a sufficient severity to compromise an indi-
vidual’s daily function.2 It causes huge social and economic 
burden such as the estimated cost of care for global patients 
of AD and dementia is equivalent to 1% global gross domes-
tic product.3 Currently, 47 million global people live with 
dementia, and this figure is projected to rise to 74 million by 
the year 2030.4 Even after a century of its discovery, effective 
therapy is still not available which could prevent, cure, and 
even stop its progression.5 Drug development for AD has 
also become a holy grail as 99.6% failure rate is encoun-
tered in clinical trials.6 The complexity of the disease is the 
main reason for several failures in clinical trials due to the 
involvement of multiple pathways in the development and 
progression of the disease such as amyloid-beta (Aβ) plaques, 
phosphorylated tau neurofibrillary tangles, oxidative stress, 
neuroinflammation, mitochondrial dysfunctions, glial acti-
vation, synaptic dysfunction, and neurotransmission-related 
mechanisms.2,7,8 Most mechanisms form vicious cycles to 
accelerate the disease progression. Thus, targeting multiple 
key pathways of AD pathogenesis is the key to the successful 
therapeutic outcome.2,9
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, 
MCI-186, EDR) is a free radical scavenger, developed 
by Mitsubishi Tanabe Pharma Corporation (Osaka, Japan). 
It has been approved for the treatment of acute cerebral 
infarction in Japan and amyotrophic lateral sclerosis (ALS) 
in the USA and Japan.10,11 The protective effect of EDR 
against AD-like insults in neuroblastoma N2a cells was 
reported by attenuating cytochrome c release, suppressing 
the activation of caspase-3 and decreasing the Bax/Bcl-2 
ratio.12 Also, its inhibitory effect on amyloid-β precursor 
protein (APP) processing and enhancing nonamyloidogenic 
pathway for the regulation of Aβ production by using human 
“Swedish” APP mutation APP695 (SY5Y-APP695swe) 
was shown by downregulating beta-secretase (BACE1) in a 
dose-dependent manner.13 Also, its efficacy in streptozotocin-
induced and Aβ-induced rat models have been demonstrated 
by improvement against the cognitive dysfunction.14–16 
Moreover, its therapeutic potential in double transgenic 
(Tg) APPSwe/PS1deE9 (APP/PS1) mice after 3 months of 
treatment was revealed by targeting multiple pathologies 
such as Aβ, oxidative stress, tau hyperphosphorylation, 
synaptic dysfunction, neuronal loss, neuroinflammation, 
and glial activation and improving the behavioral deficits.2 
The dose-dependent efficacy assessment of EDR is yet to 
be explored as it showed a dose-dependent effect against 
cerebral arachidonate cascade,17 cardioembolic stroke,18 and 
neonatal hypoxic-ischemic encephalopathy.19
Among the various routes of drug delivery, the oral route 
is accepted as the most favored by the patients as well as 
clinicians. The poor oral bioavailability (BA) due to poor 
aqueous solubility, stability, dissolution, and permeability 
has been reported for EDR. It was considered as one of the 
potential reasons for the failure of a number of potential 
drugs including curcumin in clinical trials.20,21 Thus, there 
is a need for the appropriate oral formulation to conduct 
the clinical trials for its safety and efficacy study at a large 
scale for the development of EDR as a drug for AD-like 
chronic diseases. Several efforts have been reported for the 
improvement of its oral BA; however, these investigational 
findings have not yielded significant success for effectively 
translating their use for clinical purpose.11,22–24 The novel 
edaravone formulation (NEF) was developed in part I of 
this study, by using the strategy called self-nanomicellizing 
solid dispersion which is the combination of solid disper-
sion and nanomicelles strategies. There was a significant 
dose-dependent enhancement of oral BA of 10.2, 16.1, and 
14.8-fold compared to EDR suspension for 46, 138, and 
414 µM/kg doses of EDR. The dramatic improvement of 
solubility, stability, dissolution, intestinal permeability, 
and inhibitory effect on glucuronidation contributed to the 
exceptional outcome. Previously, several nanoformulations 
of drugs showed significantly better efficacy than the crude 
drugs for AD probably by improving oral BA.25,26 Therefore, 
we assessed the efficacy of NEF in AD mouse model in the 
second part of the study in the present paper.
AD is a progressive and irreversible brain disease in which 
a steady decline in cognitive, behavioral, and physical abili-
ties is the key clinical manifestation. Memory loss is one of 
the main clinical manifestations of AD; hence, the efficacy 
of any potential intervention candidates could be judged 
based on its ability to prevent or restore learning and memory 
ability.27 Furthermore, progressive cognitive impairment is 
always accomplished with the progression of the pathogenesis 
of AD such as Aβ accumulation, downstream pathological 
events such as oxidative stress, tau hyperphosphorylation, 
glial activation, neuroinflammation, neuronal loss, and 
synaptic dysfunction.28 The potential therapeutic candidates 
that significantly inhibit the downstream pathologies could 
improve the behavioral deficits of APP/PS1 mice.2 Thus, 
the improvement in behavioral deficits was considered as a 
marker for the efficacy of NEF and evaluated by well-accepted 
behavioral tests such as open-field, novel objective recogni-
tion test (NORT), Y-maze, and Morris water maze (MWM) 
tests.2,29 The information regarding the toxicity of EDR via 
oral administration and Soluplus® (SOL)-based preparation 
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are very limited, thus it is necessary to evaluate the safety of 
NEF to provide guidance for clinical applications.
The work reported here aimed to evaluate the safety and 
efficacy of NEF in vitro with SH-SY5Y695 APP human 
neuroblastoma cell line, followed by in vivo using transgenic 
AD mouse models in a dose-dependent manner for long-term 
exposure (3 months) via the oral route.
Materials and methods
Materials
EDR made by Aldrich Chemical Co with 99% purity was 
bought from Aladdin Industrial Corporation (Shanghai, 
China). SOL was gifted from BASF Australia Ltd (Victoria, 
Australia). DMEM, fetal bovine serum (FBS), penicillin, 
streptomycin, and l-glutamine were purchased from Life 
Technology (Victoria, Australia). Acetic acid was obtained 
from Chem Supply (South Australia, Australia). High-
performance liquid chromatography-grade ethanol and 
methanol were purchased from Merck (Victoria, Australia). 
High purity (Milli-Q) water from Millipore Ultra-Pure Water 
System (Millipore, North Ryde, NSW, Australia) was used 
throughout the study. All other reagents were of analytical 
grade. 
in vitro neuroprotection assay
MTT assay
Human neuroblastoma cell line SH-SY5YAPP695 was used 







, and Aβ42 following the protocol 
reported in our previous study.22 Briefly, SH-SY5YAPP695 
cells were seeded in a 96-well plate by using DMEM contain-
ing FBS (10%), l-glutamine (2 mM), penicillin (50 IU/mL), 
and streptomycin (50 IU/mL) in a humidified incubator 
accompanied with 95% air and 5% CO
2
 at 37°C. The cells 
were treated with CuSO
4




 (50 µM), and A-β 42 
(1 µM) to induce cytotoxicity. The dosage of EDR and NEF 
(3 µM and equivalent dose to 3 µM of EDR) was decided 
based on our previous study.2,22 After incubation time (19 h), 
MTT reagent (25 µL) was added and incubated at 37°C for 
an hour. After discarding MTT reagent, dimethyl sulfoxide 
(200 µL) was used to solubilize the intracellular formazan 
crystals, and the color intensity was measured at 570 nm by 
using multi-well scanning spectrophotometer (WALLAC 
1420; PerkinElmer Inc, Waltham, MA, USA). 
in vitro cellular uptake study
The cellular uptake of EDR and NEF in SH-SY5YAPP695 
cells was studied as per the protocol reported in our 
previous publication.22 After seeding cells with density 
2×105 cells/mL in a 6-well plate, cells were treated with EDR 
(3 mM) and NEF containing equivalent concentrations of 
EDR (3 mM) for 0.5 and 2 h. Later, the cells were washed 
three times with cold PBS, followed by lysing by using radio-
immunoprecipitation assay buffer. Liquid chromatography-
mass spectrometry was used to quantify EDR in order to 
determine the cellular uptake at 0.5 and 2 h.
Behavioral tests 
suitability of drinking water to supply neF
The behavior of animals could be adversely affected due 
to daily gavage or injection for 3 months. Supplying with 
drinking water was considered as the best way to perform 
long-term safety and efficacy study. The acidic water (pH of 
2.5–3.0) is provided to the animals to prevent the spread of 
bacterial disease.30,31 Thus, stability study was conducted to 
investigate the suitability of drinking water to supply NEF. 
To determine the stability of NEF, 300 mL of the formula-
tion at the concentration equivalent to 0.27 (46 µM/kg), 
0.82 (138 µM/kg), and 2.48 mM (414 µM/kg) of EDR using 
NEF was prepared and filled in the water bottles. The dosage 
was determined by the measurement of the volume of water 
consumed by the mice prior to drug delivery. These bottles 
were stored at room temperature in the animal house facility. 
The samples were collected at predetermined time intervals 
and loaded in high-performance liquid chromatography for 
further analysis after dilution and filtration. 
animals
APP/PS1 transgenic mice with C57BL/6 background was 
procured from Jackson Laboratory, Inc (West Grove, PA, 
USA). The animal ethics committee of the University of 
South Australia approved animal ethics for breeding proce-
dures and the experiments under South Australian Animal 
Welfare Act 1985. The breeding was done in the Reid animal 
facility of the University of South Australia. The standard 
conditions were maintained, which include standard light/
dark cycles of 12 h each, the temperature of 22°C±1°C, and 
humidity of 52%±2%. All the animals were assessed for 
their health, general behavior, and appearance to confirm 
the suitability for the whole experiment.
Based on our previous publications, SD was determined 
within the 20% of means. Thus, sample size (n=8–12) was 
calculated for the detection of the difference of 20% between 
groups at beta level of 80% and alpha at 5%.2,29 The APP/PS1 
(at the age of 14 months) was randomly divided into seven 
groups mentioned in Table 1. The group of 17-month-old 





wild-type (WT) C57BL/6 mice supplied with normal 
drinking water was utilized as a positive control for the 
behavioral tests. The required amount of SOL and NEF 
were dissolved in drinking water, filtered, and supplied to 
animals as per the requirement. For donepezil (DNP), Aricept 
tablet (Pfizer, Inc, New York, NY, USA) was crushed using 
mortar and pestle and mixed with the required quantity of 
drinking water, filtered, and supplied to the animals. Open-
field, NORT, Y-maze, and MWM tests were conducted to 
investigate the effect of 3 months of treatment of NEF on 
change in the behavioral phenotype of APP/PS1 compared 
to the control groups. All behavioral tests were carried out 
in isolated behavior room in the Reid animal facility. To 
acclimate to the environment, animals were moved to the 
behavior room 1 h before initiating the test. ANY-maze video 
tracking software (Stoelting Co., Wood Dale, IL, USA) and 
a digital camera were used to record the animal behaviors as 
per the previous reports.2,29,32 The persons who did behavioral 
tests were blind to the group identities, and all data were 
analyzed according to precoded labels. The results were 
revealed after the data analysis was completed.
Measurement of water and food consumption
To determine the appropriate dosing, average water and 
food intake of the animals were recorded. The animals were 
divided into different groups, and average water and food 
consumption was documented up to 14 days before and after 
the addition of NEF to confirm the appropriate dosing. The 
initial amount and the amount left at the end of the day were 
recorded to get the amount consumed over a period. 
Open-field test
The white square open arena with an area of 40×40×40 cm 
was used for the test. Each animal was placed gently at the 
center of the arena, letting them move freely for the first 
5 min. Each test lasts for about 10 min, and the arena was 
cleaned by using 70% ethanol and water after each trial. 
In this test, a number of various conventional and ethological 
parameters were recorded during each session including 
1) spontaneous locomotor activity assessed by the entire 
distance covered and the number of rearing and 2) anxious 
behavior determined by the % time spent in the central arena, 
the number of grooming, defecation, and urination.32
novel objective recognition test
NORT test assesses the mice’s ability to identify the novel 
object in the environment. The experiment was carried out 
in the same arena used in open-field test. The test was con-
ducted in the three different phases that include 1) habitua-
tion; 2) familiarization; and 3) test phase. During habituation 
phase, each mouse was allowed to explore the whole arena 
without any objects. The mouse was then removed from the 
arena and put back into the holding cage. In the familiariza-
tion phase, the mouse was kept for some time in the open 
arena consisting of two identical objects (a+a). In the final 
testing phase, one of the identical objects was replaced with 
the novel object and the mouse was then kept in the white 
open arena composed of one identical and one novel object 
(a+b). In the second and third phases, the objects were kept in 
the opposite direction and 15 cm away from each other. Here, 
the time spent close to the familiar object versus the time 
spent close to the novel object on days 2 and 3 were recorded 
to generate the recognition and discrimination index.33 The 
ratio of time spent exploring one object over the total time 
spent in exploring both the objects was calculated as a recog-
nition index. The equation [DI=(TN−TF)/(TN+TF)], where 
time spent to explore the novel object (TN) and familiar 
object (TF) was used to calculate discrimination index.
Table 1 experimental design for behavioral tests with mouse models of aD





normal control normal drinking water – 17 mo WT ctrl 17 8
Basal control normal drinking water – 14 mo Tg ctrl 14 11
sham control normal drinking water – 17 mo Tg ctrl 17 12
Bc sOl – 17 mo Tg Bc 17 10
neF treated neF lD 46 µM/kg 17 mo Tg neF lD 17 11
neF treated neF MD 138 µM/kg 17 mo Tg neF MD 17 12
neF treated neF hD 414 µM/kg 17 mo Tg neF hD 17 9
DnP DnP 5.27 µM/kg 17 mo Tg DnP 17 9
Abbreviations: AD, Alzheimer’s disease; LD, low dose; MD, medium dose; HD, high dose; Tg, transgenic mice; DNP, donepezil; NEF, novel edaravone formulation; 
Bc, blank control; WT ctrl, wild-type control; sOl, soluplus.
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Y-maze test
Y-maze spontaneous alteration test was carried out to assess 
the willingness of mice to discover new environment. 
An immediate spatial working memory was evaluated by 
using a Y-shaped maze composed of three opaque arms at the 
angle of 120° from each other as per the previous study.2 The 
mouse was kept at the center of the opaque block and allowed 
to walk freely during 5-min session. The movement of each 
mouse on the opaque block was visually recorded. Alteration 
means successive entry to each arm when performed. The 
% alteration was calculated based on the actual alterations 
to possible alterations. For the novel arm exploration, the 
mouse was kept on any of the two arms and allowed to walk 
through the opaque block during the 5 min of the first session. 
In the second session, the mouse was allowed to explore all 
three arms and to discover the novel arm. The total number 
of entries in the novel arm and the time spent on the novel 
arm were recorded. 
MWM test
A circular arena of 120 cm diameter and 45 cm height was 
used to carry out the MWM test as per the previous reports.2,32 
The test apparatus was filled up to the height of 30 cm with 
water having a temperature of 23°C–25°C. The water was 
made cloudy using a nontoxic white dye prior to initiating 
the test. The MWM test pool was theoretically divided into 
four different parts. In one of the four quadrants, a white 
platform of 7.5 cm diameter was placed, and others were 
marked in accordance with the testing quadrant with left, 
right, and opposite. The mice were allowed to freely swim 
in the pool for ~1 min so as to adjust themselves in the test-
ing environment (habituation phase). Here, the mice were 
trained in two phases known as visible and hidden phases. 
In the visible phase, the platform was 0.5 cm above the water 
level, whereas in the hidden phase, the platform was below 
0.5 cm water level. Here, the training to find out a visible 
platform was given for 1 day (60 s/trial, 3 trials/d), and for 
the hidden platform, the training was given for 4 days (60 s/
trial, 3 trials/d). The animals were allowed to swim from each 
quadrant except the quadrant closer to the platform during 
each trial for up to 60 s. They were led to the platform if they 
could not find it by themselves within 60 s and allowed to 
be there for 30 s. Moreover, they were allowed to be on the 
platform even if they find it in 60 s. The probe test (single trial 
of 60 s) without a platform for each mouse was performed on 
the last day of the study. The escape latency curve, swimming 
speed, and path length (habituation phase) in platform trials, 
while a number of annulus crossing and time spent in target 
quadrant compared to all other quadrants were recorded. 
assessment of long-term repeated dose 
toxicity
Body weight
Once the treatment was initiated, the weight of each mouse 
was documented on daily basis for up to 2 weeks and then 
on weekly basis.
Water and food consumption
Food and water consumption (g/d/10 g body weight) were 
recorded during the whole treatment period on weekly basis.
general behavior and mortality
All the mice were monitored for any abnormal behavior and 
symptoms every day such as mortality or morbidity, dull/ruffled 
coat, hunched posture, reluctant to move, dehydration by skin 
tent, diarrhea/abnormal bloating, changes in skin and fur, eyes 
and mucous membranes, and behavior patterns.34 The clinical 
record sheet for each group was maintained for everyday and 
was recorded up to 3 months. The individual clinical record 
sheet was used for mice with abnormal behavior or symptoms 
for close monitoring. The weight loss of .10% was used as a 
standard for humane killing under veterinary advice.
hematological parameters
To investigate the different hematological parameters, the 
blood samples were collected in the EDTAK
2
-coated vials 
at the end the experiment. A fully automated five-part dif-
ferential hematology analyzer (Sysmex XN550, Sysmex 
Europe GmbH, Norderstedt, Germany) was used for the 
analysis of hematological parameters such as white blood 
cells, red blood cells, hemoglobin, hematocrit, mean corpus-
cular volume, mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration, platelets (PLT), mean 
platelet volume, platelet hematocrit, platelet distribution 
width, neutrophils, lymphocytes, monocytes, eosinophils, 
and basophils.35 
coagulation parameters
Different coagulation parameters including prothrombin 
time (PT) and activated partial thromboplastin time (APTT) 
were measured manually by using blood plasma. For PT 
estimation, the Innovin reagent was preheated at 37°C by 
using a water bath. 100 µL of plasma was taken in the glass 
test tube. In the glass test tube with plasma, 200 µL of the 





previously heated Innivon reagent was added, and the time 
for the fibrin strand formation was recorded. In case of APTT 
determination, APTT reagent and 0.025 M calcium chloride 
were preheated at 37°C. 100 µL of plasma sample was 
mixed with 100 µL of APTT reagent in the glass test tube. 
The resultant mixture was then incubated for 180 s at 37°C. 
In the above mixture, 100 µL of the calcium chloride was 
added and the time to start the fibrin strand formation (first 
appearance of the fibrin) was documented at 37°C. Analysis 
of each sample was performed in triplicate.
serum biochemistry
An automatic biochemistry meter (SELECRTA-E; Vital Sci-
entific, Van Rensselaerweg, AV Spankeren, the Netherlands) 
was used to measure the different biochemical parameters 
such as alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, amylase, lipase, gamma-glutamyl 
transferase, sodium, bicarbonate, anion gap, potassium, 
calcium, sodium:potassium ratio, chloride, inorganic phos-
phorus, calcium:phosphorus ratio, albumin, total protein, 
globulin, total bilirubin, creatinine, urea nitrogen, glucose, 
and total cholesterol. 
Organ weight
Each animal was euthanized by carbon dioxide inhalation and 
perfused intracardially with cold PBS (pH 7.4) after complet-
ing the experiment. Different organs including brain, stom-
ach, small intestine (SI), large intestine (LI), liver, kidneys, 
spleen, and heart were collected and weighed individually. 
histopathology
The histopathological examination was performed on all the 
collected tissues including brain, stomach, SI, LI, liver, kidneys, 
spleen, heart, and lungs. The tissues were fixed in 10% formalin 
and subsequently processed in Fully Enclosed Tissue Processor 
(Leica ASP300, Leica Microsystems Pty Ltd, Mt Waverley, 
VIC, Australia) with a routine schedule of treatments of 70% 
ethanol, 90% ethanol, absolute ethanol, xylene, and paraffin wax 
(Table S1). The tissues were embedded in the paraffin (Leica EG 
1160) prior to taking standard sections via Microm Microtome 
and histology water bath (Leica HI1210). The sections were 
then stained with H&E dye and observed under the microscope 
(Olympus CX 41; Olympus Corporation, Tokyo, Japan).36
statistical analysis
Mean and SD or mean and standard error of the mean was 
used to express all values. The statistical analysis of data was 
conducted by using GraphPad Prism 6 (GraphPad Software, 
Inc, La Jolla, CA, USA) for normal distribution first by 
using Shapiro–Wilk test followed by Student’s t-test for two 
groups, one way and two-way analysis of variance for mul-
tiple groups. P-values ,0.05 were considered significant.
Results and discussion
in vitro neuroprotection assay
Therapeutic efficacy of EDR and NEF was investigated by 
using human neuroblastoma cell line which is most widely 
accepted to test the neuroprotection in vitro.22 In AD patho-
genesis, the viability of neuron is significantly affected with 
cytotoxicity induced by hydrogen peroxide, copper metal 
ions, and Aβ42.2,22 The statistically significant neuroprotec-
tion action was observed in the treatment group EDR and 
NEF compared to nontreated group against cytotoxicity by 




 (Figure 1B; 
Table S3), and Aβ42 (Figure 1C; Table S4). Moreover, NEF 
showed better neuroprotection compared to EDR; however, it 
was nonsignificant statistically. The results of cellular uptake 
demonstrated that NEF was internalized more efficiently 
compared to crude EDR at 0.5 and 2 h (Figure 1D; Table S5). 
The results of significant enhancement in cellular uptake and 
neuroprotective effect of NEF demonstrated that NEF may 
be useful as a potential anti-Alzheimer drug and considered 
for further evaluation in vivo.
Behavior tests
The purpose of the study was to determine the therapeutic 
potential of NEF against AD, and for that, suitable animal 
model, age, duration of treatment, and evaluation tests were 
the key requirements. The ideal animal model should closely 
mimic the symptoms and neuropathology of AD disease. 
APP/PS1 mouse model was created by expressing variants 
of chimeric human APP and a mutant human presenilin 1.37 
It is well accepted to investigate the therapeutic potential 
candidates against AD because it showed key characters 
such as cognitive dysfunction as a result of pathological 
changes manifested by senile plaques, neuroinflammation, 
and neuronal loss. The potential therapeutic candidates such 
as EDR,2 docosahexaenoic acid,38 Puerarin,39 and p75NTR 
ectodomain protein29 ameliorated the cognitive dysfunction 
in APP/PS1 mice by improving AD-like pathology. There-
fore, the efficacy of NEF against AD was evaluated based 
on its potential to improve learning and memory in AD 
mice. In addition, the age-dependent cognitive decline was 
observed with APP/PS1 mouse models; hence, selection of 
suitable age is critical. The 14 months of age for APP/PS1 
mice as a starting point because of the fully developed 
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AD-like pathology and behavioral deficits similar to the 
clinical AD was observed in the previous studies.28 More-
over, due to the chronic nature of AD, 3 months of the 
treatment period was selected as appropriate for efficacy 
evaluation from the previous report.2 As an improvement of 
learning and memory of APP/PS1 mice used as a marker in 
evaluating efficacy against AD, a number of behavior tests 
were selected to assess the motor function (open field), 
anxiety-related behavior (open field), and cognitive function 
(NORT, Y-maze, and MWM). APP/PS1 mice showed AD-
like behavioral deficits in the open-field, NORT, Y-maze, and 
MWM tests.2,29,40 A group of C57BL/6 WT mice was used 
as a normal aging control as APP/PS1 mice were genetically 
modified mice with the background of C57BL/6. One group 
of APP/PS1 mice aged 14 months was considered as a basal 
control, which had undergone for the behavioral tests at the 
starting point of treatments. Other groups of mice were used 
as a negative control without any treatment, blank formula-
tion control (without EDR), and DNP-positive control group 
(for details of grouping designs, see Table 1). All behavioral 
tests were conducted at 17 months similar to NEF treatment 
groups, except the basal control group which was done at 
14 months. The data of control groups such as 17 mo WT 
Ctrl, 14 mo Tg Ctrl, 17 mo Tg Ctrl, 17 mo Tg BC, and 
17 mo Tg DNP are used in other similar projects to reduce 
the utilization of an overall number of animals as per the 
animal ethics guideline.
Daily injection or gavage for 3 months could affect the 
behaviors of mice and impact on the outcome as well as a 
welfare issue. Therefore, mixing of NEF with drinking water 
β β β
Figure 1 In vitro safety and efficacy of NEF compared with EDR in SH-SY5Y695 cell line. 
Notes: effect of eDr and neF on cell viability in the presence of cusO4 (A), h2O2 (B), and aβ42 (C). In vitro cellular uptake efficiency of NEF and EDR in SH-SY5Y695 
cell line after incubating for 0.5 and 2 h (D) (mean±se, n=3). *P,0.05 and **P,0.01. One and two-way ANOVA and Sidak’s multiple comparisons test. Data for EDR were 
adapted from the earlier report.22
Abbreviations: neF, novel edaravone formulation; eDr, edaravone; anOVa, analysis of variance.





was selected to allow voluntary oral administration of NEF, 
Blank formulation and DNP. In animal house facility, acidic 
drinking water was used to avoid the spreading of bacterial 
infections among the animals in a cage.30,31 Thus, evaluating 
the stability of NEF in acidic drinking water was performed 
to determine its suitability as an administration technique 
and frequency of changing the water bottle. The frequency of 
changing water bottle in our animal house facility was weekly 
as per the standard; hence, stability study was conducted for 
7 days. Less than 1% decrease in EDR content with all three 
doses of NEF was detected in 1 week, which confirmed the 
suitability of mixing NEF with acidic drinking water as a 
way of administration. The concentration of NEF, SOL, and 
DNP in acidic drinking water was calculated for appropriate 
dosing as per the data of average water consumption and 
weight of the mice mentioned in Table 2. The amount of 
water intake was used to calculate the dose for the prepara-
tion of drinking water mixed with the different doses of NEF, 
blank formulation, and DNP. 
Open-field test
The locomotor and exploration activity (measuring total 
distance traveled and the number of rearing) and anxiety 
behaviors (% time spent in the central zone and number of 
rearing, grooming, urination, and defecation) of all APP/PS1 
mice were evaluated by open-field test.29 There was a signifi-
cant decrease in locomotor and exploration activity as well as 
high level of anxiety observed at 14 and 17 months of age of 
APP/PS1 mice without any treatment and with blank formu-
lation treatment compared to WT control mice. The treatment 
groups with NEF displayed dose-dependent increase in the 
locomotor activity, which revealed a statistically significant 
increase in total distance traveled (Figure 2A; Table S6) 
and number of rearing (Figure 2B; Table S6). Moreover, 
mice treated with NEF with middle dose (MD) and high dose 
(HD) but not low dose (LD) spent significantly longer time in 
the central zone (Figure 2C; Table S6), which indicated the 
lowering of anxiety-type behavior. Also, NEF-treated mice 
showed decreased but not statistically significant number 
of grooming (Figure 2D; Table S6), urination (Figure 2E; 
Table S6), and defecation (Figure 2F; Table S6). Besides, 
the DNP-treated mice showed similar results to the mice 
treated with NEF LD, but NEF MD- and HD-treated mice 
revealed better performance than DNP-treated mice. There 
was no statistically significant difference in locomotor and 
exploration activities and anxiety behaviors of NEF-treated 
mice with standard WT mice, suggesting a potential of NEF 
treatment on the reversal of the behavioral deficits to the 
normal level. It is worthy to note that the NEF groups with 
all dosages performed better than the basal control group at 
14 months on the total travel distance, number of rearing, 
and the time spent in the central zone in the open-field test 
(Figure 2A–C), suggesting that the NEF treatment can reverse 
the mood status of aged AD mice to a much younger age.
novel objective recognition test 
The NORT reflects the learning and memory of mice based 
on their natural tendency of exploring novel object instead of 
familiar one after exposed to a novel environment.41 The poor 
performance of APP/PS1 in NORT made it an ideal study 
to examine the potential of intervention therapy for AD.42 
All APP/PS1 and WT mice showed statistically insignificant 
difference in recognition index in the phase of familiarization 
(Figure 3A; Table S7). In the test phase, the 17-month-old 
Table 2 Measurement of food and water consumption and body weight of Tg mice (mean±sD, n=5)
Parameter Time APP/PS1 mice
17 mo Tg 
Ctrl
17 mo Tg 
BC
17 mo Tg 
NEF HD
Food intake 
(g/d/10 g body weight)
Before addition (14 months)*







at 17 months 1.22±0.31 1.24±0.22 1.19±0.25
Water intake 
(g/d/10 g body weight)
Before addition (14 months)*







at 17 months 1.25±0.20 1.27±0.28 1.23±0.27
Body weight (g) Before addition (14 months)* 33.13±3.24 33.9±4.82 32.81±2.59
after addition (14 months)+ – 34.6±3.45 34.32±2.99
at 17 months 34.15±3.13 34.24±3.17 34.58±3.12
Notes: *Before addition of treatment such as blank formulation (17 mo Tg Bc) and neF (17 mo Tg neF hD). +after addition of treatment such as blank formulation 
(17 mo Tg Bc) and neF (17 mo Tg neF hD).
Abbreviations: Tg, transgenic mice; 17 mo Tg ctrl, 17-month-old transgenic sham control mice; 17 mo Tg Bc, 17-month-old transgenic blank control mice; 17 mo Tg neF 
hD, 17-month-old transgenic mice treated with high dose of neF; neF, novel edaravone formulation.
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Figure 2 Results of open-field test. 
Notes: Total distance traveled (A), number of rearing (B), time spent in central zone (C), number of grooming (D), number of urination (E), and number of defecation (F). 
*P,0.05, **P,0.01, ***P,0.001, and ****P,0.0001 (one-way ANOVA, Tukey’s test) (mean±seM).
Abbreviations: neF, novel edaravone formulation; 17 mo WT ctrl, 17-month-old normal wild-type control mice; 17 mo Tg ctrl, 17-month-old transgenic sham control mice; 
14 mo Tg ctrl, 14-month-old transgenic mice as a basal control; 17 mo Tg Bc, 17-month-old transgenic blank control mice; 17 mo Tg neF lD, 17-month-old transgenic mice 
treated with low dose of neF; 17 mo Tg neF MD, 17-month-old transgenic mice treated with medium dose of neF; 17 mo Tg neF hD, 17-month-old transgenic mice treated 
with high dose of neF; 17 mo Tg DnP, 17-month-old transgenic mice treated with high dose of donepezil; seM, standard error of the mean; anOVa, analysis of variance.





APP/PS1 mice without any treatment and with blank formu-
lation treatment showed no tendency to explore the novel 
object, while NEF-treated mice presented significantly higher 
and dose-dependent increase in the discrimination index 
(Figure 3B and C; Tables S7 and S8). Moreover, NEF-treated 
mice with all doses displayed significantly better performance 
in a dose-dependent manner compared to the basal control 
at 14 months. DNP-treated mice reflected the improvement 
of AD-related deficits to the much younger aged mice and 
better than untreated control groups. The performance of 
NEF-treated mice evaluated based on discrimination index in 
test phase was comparable to WT normal mice at 17 months 
and better than the positive control DNP group. These results 
suggest that NEF treatment at all dosages can reverse the 
cognitive decline to the much younger age of AD mice and 
to the level near WT normal aging mice. 
Y-maze test
Mouse has a natural tendency to explore a novel environ-
ment, but AD-like cognitive deficits could affect its ability 
Figure 3 results of nOrT. 
Notes: recognition index in the phase of familiarization (A) and the test phase (B), discrimination index in the test phase (C). ****P,0.0001 (one-way ANOVA, Tukey’s test) 
(mean±seM).
Abbreviations: neF, novel edaravone formulation; nOrT, novel objective recognition test; 17 mo WT ctrl, 17-month-old normal wild-type control mice; 17 mo Tg ctrl, 
17-month-old transgenic sham control mice; 14 mo Tg ctrl, 14-month-old transgenic mice as a basal control; 17 mo Tg Bc, 17-month-old transgenic blank control mice; 
17 mo Tg neF lD, 17-month-old transgenic mice treated with low dose of neF; 17 mo Tg neF MD, 17-month-old transgenic mice treated with medium dose of neF; 17 mo 
Tg neF hD, 17-month-old transgenic mice treated with high dose of neF; 17 mo Tg DnP, 17-month-old transgenic mice treated with high dose of donepezil; seM, standard 
error of the mean; anOVa, analysis of variance.
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to discriminate between familiar and novel environment.43 
Y-maze test was conducted in two phases including 
spontaneous alternation and novel arm exploration tests.2,29 
The performance of APP/PS1 mice without any treatment and 
treated with blank formulation was poor in both the phases 
compared with WT control, which indicated AD-like behav-
ioral deficits such as impairment in remembering the already 
explored arm in spontaneous alternation and the previously 
blocked arm in novel arm exploration test. The NEF-treated 
mice showed the significantly greater number of alteration 
(Figure 4A; Table S9) and entry to each arm (Figure 4B; 
Table S9) in a dose-dependent manner compared to control 
mice without any treatment or treated with the SOL vehicle. 
Moreover, significantly higher number of entry (Figure 4C 
and D; Table S9) and time spent (Figure 4E; Table S9) in 
the novel arm in comparison with other arms were witnessed 
in NEF-treated mice compared with the mice without any 
treatment or treated with the vehicle. All NEF-treated mice 
performed better than the basal control mice at 14 months of 
age, indicating that the NEF treatment can reverse the cogni-
tive status to a much younger age than 14 months, although 
these basal control younger mice performed slightly better 
than 17-month-old untreated controls but had no statistical 
difference. Also, NEF-treated mice showed better results 
but statistically insignificant compared with mice treated 
with DNP in both the phases. Also, most importantly, the 
performance of NEF-treated mice in both the phases was not 
statistically different from that of WT normal aging control, 
indicating amendment by NEF at all dosages in AD-like 
cognitive functions to the normal mice with same age.
MWM test
The MWM test is one of the most sensitive tests which 
represents the AD-like deficits as it examines the function 
of the hippocampus, the most affected region of the brain 
in AD. The determination of hippocampal spatial memory 
deficits was performed by motivating mice to escape from 
water by finding the platform after placing into the water 
tank.2,29 The test was performed in four phases including 
habituation, visible platform, hidden platform, and probe 
test. The performance of all APP/PS1 and WT mice in first 
and second phases was evaluated by measuring the path 
length (Figure 5A; Table S10), swimming speed (Figure 5B; 
Table S11), and escape latency time, which was not sig-
nificantly different among groups, which indicated that all 
groups had similar motor and visual capabilities. The learning 
and memory of all mice were assessed in the third phase by 
comparing escape latency time (Figure 5C; Table S12) and 
the fourth phase by measuring a number of annulus crossing 
(Figure 5D; Table S13) and time spent in target quadrant 
compared with all other quadrants (Figure 5E; Table S14) 
of MWM. The mice without treatment or treated with the 
blank formulation in APP/PS1 mice at 14 or 17 months dis-
played significantly impaired learning compared with WT 
mice. NEF-treated mice performed significantly better in a 
dose-dependent manner showing a reduction in the escape 
latency time in the third phase and a higher number of annulus 
crossing, and longer time spent in the target quadrant in the 
fourth phase, compared with those of untreated or vehicle-
treated mice in both the phases. Moreover, these mice treated 
with MD and HD of NEF exhibited better performance than 
the DNP group. Again, the most important finding is that all 
mice treated with NEF improved their capacity of learning 
and memory to the extent comparable to the level of WT, as 
no statistical difference was seen between the WT normal 
aging control and NEF-treated groups. 
Overall, the performance of untreated or blank formula-
tion treated mice at 17 months showed AD-like behavioral 
deficits in open-field, NORT, Y-maze, and MWM behavior 
tests compared with WT control. The basal control group 
of mice presented slightly better but insignificant than 
17-month-old mice, while blank formulation treatment 
did not show any improvement compared with 17-month-
old untreated mice. DNP treatment rescues the cognitive 
deficits of APP/PS1 mice in all behavioral tests compared 
with 17-month-old untreated mice but only able to match 
the performance of NEF LD treatment. The NEF MD- and 
HD-treated mice revealed exceptional learning and memory 
ability which was better than DNP-treated, basal control and 
quite similar to the WT control mice in all behavior tests. 
The expressed NEF treatment could not just prevent the 
deterioration of cognitive functions but also made a reversal 
of AD-like behavioral deficits in APP/PS1 mice similar to 
the much younger mice or same age normal mice. 
Previously, EDR ameliorates the AD-like memory deficits 
in APP/PS1 mice by reducing Aβ deposition and alleviates 
oxidative stress and attenuates the downstream pathologies 
including tau hyperphosphorylation, glial activation, neu-
roinflammation, neuronal loss, and synaptic dysfunction.2 
Moreover, it also showed improved streptozotocin-induced 
cognitive damage by reducing oxidative stress and hyper-
phosphorylation of tau.15 In addition, EDR amended spatial 
learning and memory deficits in Aβ-induced neurotoxicity 
in rats by lowering 4-hydroxynonenal level, acetylcholin-
esterase and choline acetyl transferase activities.14 NEF 
is a more bioavailable form (.10-fold compared with 
EDR suspension) of EDR which could not only achieve 
a higher concentration in systemic circulation but also in 





Figure 4 The behavioral performances of Tg mice in Y-maze test. 
Notes: % alternation (A) and numbers of entries in each arm (B) and in the spontaneous alternation test, % of total entry in novel arm compared with other arms (C), 
total number of entry to the novel arm (D), and time (%) (E) in the novel arm test. *P,0.05, **P,0.01, ***P,0.001, and ****P,0.0001 (one-way ANOVA, Tukey’s test) 
(mean±seM).
Abbreviations: neF, novel edaravone formulation; 17 mo WT ctrl, 17-month-old normal wild-type control mice; 17 mo Tg ctrl, 17-month-old transgenic sham control mice; 
14 mo Tg ctrl, 14-month-old transgenic mice as a basal control; 17 mo Tg Bc, 17-month-old transgenic blank control mice; 17 mo Tg neF lD, 17-month-old transgenic mice 
treated with low dose of neF; 17 mo Tg neF MD, 17-month-old transgenic mice treated with medium dose of neF; 17 mo Tg neF hD, 17-month-old transgenic mice treated 
with high dose of neF; 17 mo Tg DnP, 17-month-old transgenic mice treated with high dose of donepezil; seM, standard error of the mean; anOVa, analysis of variance.
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Figure 5 The performances of Tg mice in MWM test. 
Notes: Path length (cm) to the platform (A), swim speed (cm/s) during platform trials and probe test (B), escape latency (s) during platform trials and distance travelled on 
each day of training (C), number of annulus crossings in probe trial (D), comparison of time spent in target zone (Q3) (first bar) where platform was located compared with 
the average of all other zones (o.a.) (second bar) (E). *P,0.05 and **P,0.01 (two-way or one-way ANOVA, Tukey’s test) (mean±seM).
Abbreviations: neF, novel edaravone formulation; MWM, Morris water maze; 17 mo WT ctrl, 17-month-old normal wild-type control mice; 17 mo Tg ctrl, 17-month-old 
transgenic sham control mice; 14 mo Tg ctrl, 14-month-old transgenic mice as a basal control; 17 mo Tg Bc, 17-month-old transgenic blank control mice; 17 mo Tg neF 
lD, 17-month-old transgenic mice treated with low dose of neF; 17 mo Tg neF MD, 17-month-old transgenic mice treated with medium dose of neF; 17 mo Tg neF hD, 
17-month-old transgenic mice treated with high dose of neF; 17 mo Tg DnP, 17-month-old transgenic mice treated with high dose of donepezil; seM, standard error of the 
mean; anOVa, analysis of variance.





the brain as 50%–65% of the relative ratio of plasma to the 
cerebral spinal fluid of EDR was reported previously.44 The 
dose-dependent therapeutic effect of EDR against AD in 
in vitro and in vivo studies against ALS has been already 
revealed.2,13,45 Therefore, due to the enhancement of oral 
BA of EDR, NEF could more effectively target multiple 
pathways of AD pathogenesis and thus rescue the cognitive 
deficits of a mouse model of AD.
assessment of long-term repeated dose 
toxicity
As a result of superior pharmacological properties of EDR 
against AD and the exceptional performance of NEF, a more 
bioavailable form or EDR in a behavioral study conducted 
on APP/PS1 mice, NEF could be developed as a therapeutic 
agent for AD. The available information on the toxicity of 
SOL-based preparation is very limited. Thus, as a part of 
safety assessment, the objective of this study was to evaluate 
the long-term toxicity study of NEF when supplied for con-
secutively 3 months. It could provide guidance for clinical 
applications of NEF not only for AD but various neurologic 
and nonneurologic diseases related to organs such as heart, 
lung, intestine, liver, pancreas, kidney, bladder, and testis.46 
The data of 17 mo Tg Ctrl and 17 mo Tg BC control groups 
are used in other similar projects based on SOL-based prepa-
rations to reduce the use of an overall number of animals as 
per the animal ethics guideline.
No death or clinical signs were noticed related to the 
treatment in any groups including blank formulation and NEF 
with all doses. Also, the insignificant difference was observed 
in body weight, water, and food consumption in NEF-treated 
groups compared with the nontreated group except the first 
week (Table 2). During the first week after initiating the 
treatment, an increase in water intake and weight gain but a 
decrease in food intake was noted in both blank formulation, 
and NEF-treated groups than in untreated groups. The prefer-
able taste of SOL might be the possible reason to explain the 
higher water intake, which led to a weight gain, and a slight 
and transient decrease in food intake may not affect the body 
weight. After 1 week, the water and food intake and weight 
of the mice remained consistent throughout the study. 
hematological parameter
The data of hematological parameters of NEF-treated mice 
showed a slight but not significant decrease in most of the 
parameters except MCH, PLT, monocyte, and basophil counts 
compared with nontreated mice group (Table 3). The SOL 
treatment did not cause any statistically significant increase 
and decrease in the values of various hematological parame-
ters, compared with nontreated mouse groups. The biological 
significance of the results was further assessed from the study 
of organ weight and histology of the spleen.
coagulation parameters
There was no statistically significant increase or decrease in 
the value of PT and APTT detected in the case of the NEF-
treated mice and the SOL vehicle-treated mice, compared 
with nontreated mice (Table 3). 
Blood electrolytic parameters
The results indicated that there was no statistically signifi-
cant increase or decrease in the values of blood electrolytic 
parameters between the mice treated with SOL or NEF and 
those control mice without any treatment (Table 4). 
Biochemical parameters
The analysis of serum biochemistry was performed to assess 
the impact of the treatment of NEF and SOL on the standard 
Table 3 analysis of hematological and coagulation parameters of 
Tg mice (mean±sD, n=5)
Parameters APP/PS1 mice
17 mo Tg 
Ctrl 
17 mo Tg 
BC 
17 mo Tg 
NEF HD
Hematological parameters
rBc (×1012/l) 9.52±0.39 9.38±0.51 9.12±0.47
WBc (×109/l) 7.17±3.28 7.56±3.94 6.95±3.08
hgB (g/dl) 13.64±0.45 13.95±0.61 13.28±0.62
hcT (%) 48.92±1.43 47.67±1.92 46.18±2.42
McV (fl) 49.81±1.36 48.53±1.89 49.17±2.05
Mch (pg) 14.68±0.82 15.28±0.61 14.80±0.49
Mchc (g/dl) 29.53±1.16 28.95±1.99 29.18±1.82
PlT (×109/l) 496.81±282.34 521.94±196.05 529.27±297.26
MPV (fl) 6.95±0.14 6.57±0.27 6.58±0.31
PcT (%) 0.23±0.16 0.19±0.11 0.22±0.18
PDW (fl) 8.3±1.62 8.29±1.72 7.96±2.44
neutrophils (%) 14.35±4.53 12.24±5.25 13.45±4.98
lymphocytes (%) 81.82±5.74 77.56±5.23 76.95±6.29
Monocytes (%) 4.61±2.16 5.25±2.49 4.99±2.46
eosinophils (%) 1.86±1.65 1.52±1.16 1.79±1.04
Basophils (%) 0.04±0.05 0.05±0.05 0.05±0.03
Coagulation parameters
PT (s) 10.12±0.62 10.25±1.12 12.21±2.48
aPTT (s) 26.67±8.97 28.45±8.12 26.19±9.29
Abbreviations: aPP/Ps1, aPPswe/Ps1dee9; Tg, transgenic mice; 17 mo Tg ctrl, 
17-month-old transgenic sham control mice; 17 mo Tg Bc, 17-month-old transgenic 
blank control mice; 17 mo Tg neF hD, 17-month-old transgenic mice treated with 
high dose of neF; WBc, white blood cells; rBc, red blood cells; hgB, hemoglobin; 
hcT, hematocrit; McV, mean corpuscular volume; Mch, mean corpuscular 
hemoglobin; Mchc, mean corpuscular hemoglobin concentration; PlT, platelets; 
MPV, mean platelet volume; PcT, platelet hematocrit; PDW, platelet distribution 
width; PT, prothrombin time; aPTT, activated partial thromboplastin time; neF, 
novel edaravone formulation.
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function of liver, kidneys, heart, liver, and digestive system 
of mice (Table 4). At the end of the treatment period, there 
was a slight increase in values of creatinine, total bilirubin, 
and urea in NEF- and SOL-treated groups compared with the 
untreated controls, but no statistically significant difference. 
There was no statistically significant difference in the rest of 
liver enzymes and metabolites between treated and control 
mice. These results indicate that the treatment of SOL did not 
show any significant alterations in the serum biochemistry 
compared with nontreated groups. The biological significance 
of the results was further evaluated based on the study of 
organ weight and histology study.
Organ weight 
The results of weights of all the key organs of the mice treated 
with blank formulations and NEF and without any treatment 
are presented in Table 5. The NEF-treated mice showed a 
slight increase in weight of all organs but without statistical 
significance. The average weight of NEF-treated mice was 
higher than the nontreated mice that could explain slight 
more weights of all the key organs. There was no change 
in the weight of organs in SOL-treated mice compared with 
untreated mice. 
histopathology
Histopathological examinations of the all the vital organs 
including liver, kidney, brain, heart, spleen, lung, stomach, 
SI, and LI did not reveal any treatment-related changes 
in NEF- or SOL-treated mouse group compared with 
Table 4 analysis of biochemical parameters of Tg mice (mean±sD, n=5)
Parameters APP/PS1 mice
17 mo Tg Ctrl 17 mo Tg BC 17 mo Tg 
NEF HD
sodium (mmol/l) 147.66±2.94 143.06±2.98 147.38±2.58
Bicarbonate (mmol/l) 27.16±5.79 27.9±5.02 28.31±5.48
anion gap (mmol/l) 22.78±4.70 22.91±5.25 23.46±4.68
Potassium (mmol/l) 11.06±1.52 12.94±1.03 11.00±1.26
calcium (mmol/l) 2.56±0.19 2.84±0.18 2.58±0.22
sodium:potassium ratio 13.6±1.86 13.93±1.92 13.75±1.39
chloride (mmol/l) 107.71±2.52 109.52±2.91 107.73±2.94
inorganic phosphorus (mmol/l) 3.08±0.77 3.56±0.99 3.04±0.84
calcium:phosphorus ratio 0.83±0.19 0.78±0.14 0.81±0.18
albumin (g/l) 34.93±2.68 31.16±3.57 33.45±2.48
Total protein (g/l) 56.69±3.59 54.58±4.56 57.62±3.57
globulin (g/l) 24.8±2.67 23.4±2.96 22.53±2.48
Total bilirubin (µmol/l) 0.43±0.05 0.67±0.07 0.46±0.04
creatinine (µmol/l) 10.84±2.86 12.22±4.76 14.56±3.59
Urea (mmol/l) 7.67±2.12 9.2±3.45 7.24±2.94
glucose (mmol/l) 15.96±3.15 15.06±3.78 15.64±3.26
cholesterol (mmol/l) 2.56±0.59 2.51±0.56 2.64±0.61
asT (U/l) 305.07±200.04 326.94±179.35 256.62±127.48
ggT (U/l) 0 0 0
alkaline phosphatase (U/l) 106.73±31.70 106.44±28.02 115.88±32.14
lipase (U/l) 98.86±39.77 89.28±35.14 105.46±45.20
alT (U/l) 97.01±21.15 99.64±18.04 103.54±23.28
amylase (U/l) 2,181.95±339.34 2,295.26±290.25 1,944.36±424.28
Abbreviations: aPP/Ps1, aPPswe/Ps1dee9; Tg, transgenic mice; 17 mo Tg ctrl, 17-month-old transgenic sham control mice; 17 mo Tg Bc, 17-month-old transgenic blank 
control mice; 17 mo Tg neF hD, 17-month-old transgenic mice treated with high dose of neF; alT, alanine aminotransferase; asT, aspartate aminotransferase; alP, alkaline 
phosphatase; ggT, gamma-glutamyl transferase; neF, novel edaravone formulation.
Table 5 analysis of organ weights of Tg mice (mean±sD, n=5)
Organ (g) APP/PS1 mice
17 mo Tg 
Ctrl
17 mo Tg 
BC
17 mo Tg 
NEF HD
Brain 0.48±0.08 0.49±0.07 0.49±0.08
liver 1.86±0.48 1.84±0.42 1.89±0.44
heart 0.22±0.06 0.21±0.08 0.24±0.05
lung 0.52±0.12 0.55±0.14 0.55±0.10
spleen 0.13±0.03 0.12±0.04 0.16±0.03
Kidney 0.25±0.04 0.23±0.03 0.27±0.04
Abbreviations: aPP/Ps1, aPPswe/Ps1dee9; Tg, transgenic mice; 17 mo Tg ctrl, 
17-month-old transgenic sham control mice; 17 mo Tg Bc, 17-month-old transgenic 
blank control mice; 17 mo Tg neF hD, 17-month-old transgenic mice treated with 
high dose of neF; neF, novel edaravone formulation.





nontreated mice group (Figure 6). Therefore, these results 
are consistent with no statistically significant change in the 
results observed in hematological, coagulation, blood elec-
trolytic, and biochemical parameters after the treatment of 
NEF or SOL for 3 months. These results together indicate 
that 1) different dosages of EDA 46, 138, and 414 µM/kg 
are well tolerated by animals via oral intake for 3 months 
and 2) the vehicle SOL added into the formulation did not 
alter any organ functions and is also well tolerated in mice 
fed for 3 months.
Previously, the potential of EDR as an intervention 
therapy for AD was disclosed by targeting multiple key AD 
pathways including Aβ, tau phosphorylation, oxidative stress, 
and neuroinflammation. NEF, the more bioavailable form of 
EDR, showed exceptional performance by improving AD-
like behavioral deficits near the normal level that was better 
than the already approved drug product (DNP). In addition, 
based on the long-term repeated dose toxicity assessment 
results, good tolerability of NEF was proven via the oral 
route of administration. As the oral route of administration 
is the most preferred route of administration, our study 
demonstrated NEF as a promising and very safe therapeutic 
candidate in the current preclinical development. 
Conclusion
For the first time, the greater bioavailable form of EDR- and 
SOL-based formulation, NEF, was systematically studied for 
safety and efficacy in in vitro and in vivo disease models. 
NEF showed greater cellular uptake and better neuropro-
tective effect compared with EDR against the cytotoxicity 




, and Aβ42 oligomer in 
SH-SY5Y695 cell line. In in vivo study, it showed dose-
dependent rescues of the behavioral deficits of 17-month-old 
APP/PS1 mice from the open-field, NORT, Y-maze, and 
MWM tests after 3 months of exposure. Also, it appeared 
reversing the cognitive decline of APP/PS1 mice to the cog-
nitive level of WT normal aging mice and performed better 
than DNP. Moreover, the toxicity study data revealed the 
absence of drug-induced toxicity by oral administration of 
up to 414 µM/kg of EDR in the APP/PS1 mice. Thus, NEF 
could be a promising candidate for the AD treatment. Our 
data in the present study, together with the earlier proof-of-
concept study in 12-month-old APP/PS1 mice, warrants a 
large scale of clinical trials in mild cognitive impairment and 
sporadic and familial AD.
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